Vaccination Against Extracellular Vimentin Plus Doxorubicin for Canine Hemangiosarcoma
Authors:
- Diederik J. M. EngbersenDEDiederik J. M. Engbersen
- Lobke van BergenLBLobke van Bergen
- Emma N. BosEBEmma N. Bos
- Quinty HansenQHQuinty Hansen
- Arno RoosARArno Roos
- Elisabeth J. M. HuijbersEHElisabeth J. M. Huijbers
- Erica A. FaulhaberEFErica A. Faulhaber
- Pancras C. W. HogendoornPancras C. W. Hogendoorn
- Douglas H. ThammDTDouglas H. Thamm
- Arjan W. GriffioenAGArjan W. Griffioen
Open Access
- 18 September 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 9096
Abstract
Angiosarcomas are highly aggressive soft tissue tumors with poor prognosis in both humans and dogs. In dogs, visceral hemangiosarcoma offers a relevant spontaneous model for evaluating novel therapies. Surgery alone yields a median survival of 1–3 months, and treatment with doxorubicin (DOX), alone or in combination (e.g., with propranolol), modestly extends median survival time to 5–7 months, with a 1-year survival of around 10%. We developed a conjugate vaccine technology, called immune Boost (iBoost), and hypothesized that combining DOX with an iBoost vaccine targeting extracellular vimentin (eVim) could improve survival without added toxicity. Twenty-three dogs with visceral hemangiosarcoma received six cycles of DOX every two weeks post-splenectomy, alongside four doses every other week of eVim iBoost immunotherapy, followed by maintenance vaccinations every two months. Outcomes were compared to historical controls treated with DOX alone. Compared to the control group the median overall survival time increased from 136 to 235 days (NS), restricted mean survival time at one year increased with 81 days (p = 0.02) and 1-year survival rate was 44% versus 14% (p = 0.0344). The combination was well-tolerated, with no systemic vaccine-related toxicity. Adding dog eVim vaccine to DOX appears to improve survival without added toxicity in dogs with hemangiosarcoma. These results support further clinical development, including evaluation in human angiosarcoma.Keywords
Funding Information
- EU Eurostars project SimPro (E!5706, KWF-2022-4 EXPL/14815)
- Dutch Cancer Society (E!5706, KWF-2022-4 EXPL/14815)
This publication has 47 references indexed in Scilit:
- Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockersJournal of Cancer Research and Clinical Oncology, 2025
- Propranolol monotherapy in angiosarcoma – A window-of-opportunity study (PropAngio)European Journal of Cancer, 2024
- Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergyAngiogenesis, 2022
- Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyCancer, 2022
- Multidisciplinary Management of Angiosarcoma – A ReviewJournal of Surgical Research, 2021
- Histiocytic Sarcoma and Hemangiosarcoma UpdateVeterinary Clinics of North America: Small Animal Practice, 2019
- The beta adrenergic receptor antagonist propranolol alters mitogenic and apoptotic signaling in late stage breast cancerBiomedical Journal, 2019
- Serum vascular endothelial growth factor in dogs with haemangiosarcoma and haematomaResearch in Veterinary Science, 2014
- High frequency of MYC gene amplification is a common feature of radiation‐induced sarcomas. Further results from EORTC STBSG TL 01/01Genes, Chromosomes and Cancer, 2012
- Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma groupEuropean Journal of Cancer, 2008